Rivaroxaban Induces Mucosal Healing in a Rat Model of Trinitrobenzene Sulfonic Acid-Induced Colitis

Overview

Journal Med Princ Pract

Publisher Karger

Specialties General Medicine
Medical Education

Date 2015 Jun 27

PMID 26111863

Citations 4

Authors

Ozlem Gul Utku

Eylem Akbay Karatay

Harun Erdal

Mehmet Arhan

Ibrahim Koral Onal

Mehmet Ibis

Ozgur Ekinci

Canan Yilmaz Demirtas

Selahattin Unal

Affiliations

Soon will be listed here.

Abstract

Objective: This study was designed to identify the effect of rivaroxaban, a direct factor Xa inhibitor, on trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats.

Materials And Methods: Twenty-four female Wistar rats were divided into 4 groups of 6 each. Group 1 received TNBS + rivaroxaban, group 2 received TNBS + methylprednisolone, group 3 received TNBS and group 4 received a saline enema. Colitis was induced in the rats by the intracolonic administration of TNBS. Rivaroxaban and methylprednisolone were given by oral gavage daily for 7 days. The rats were killed 7 days after the induction of colitis.

Results: Rivaroxaban and methylprednisolone significantly reduced gross damage and histopathological scores. Rivaroxaban was more effective than methylprednisolone in terms of microscopic mucosal healing. Rivaroxaban attenuated the accumulation of malonyldialdehyde (MDA) and transforming growth-factor β1 (TGF-β1) and the activities of myeloperoxidase (MPO), matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1. Methylprednisolone reduced only the activity of MPO and the accumulation of MDA and TGF-β1. Superoxide dismutase activity showed a restoration to normal levels after rivaroxaban and methylprednisolone administration.

Conclusions: Rivaroxaban showed a therapeutic effect in the TNBS model of experimental colitis, and it seemed to be at least as effective as methylprednisolone. This effect may be brought about by the inhibition of oxidative stress and metalloproteinase activity associated with tissue injury and remodeling.

Citing Articles

Antioxidant Properties of Oral Antithrombotic Therapies in Atherosclerotic Disease and Atrial Fibrillation.

Falco L, Tessitore V, Ciccarelli G, Malvezzi M, DAndrea A, Imbalzano E Antioxidants (Basel). 2023; 12(6).

PMID: 37371915 PMC: 10294911. DOI: 10.3390/antiox12061185.

Rivaroxaban Modulates TLR4/Myd88/NF-Kβ Signaling Pathway in a Dose-Dependent Manner With Suppression of Oxidative Stress and Inflammation in an Experimental Model of Depression.

Abdelzaher W, Mohammed H, Welson N, El-Saber Batiha G, Baty R, Abdel-Aziz A Front Pharmacol. 2021; 12:715354.

PMID: 34630092 PMC: 8497790. DOI: 10.3389/fphar.2021.715354.

Direct oral anticoagulants and vitamin K antagonists are linked to differential profiles of cardiac function and lipid metabolism.

Eggebrecht L, Prochaska J, Trobs S, Schwuchow-Thonke S, Gobel S, Diestelmeier S Clin Res Cardiol. 2019; 108(7):787-796.

PMID: 30604046 DOI: 10.1007/s00392-018-1408-y.

Interference With Coagulation Cascade as a Novel Approach to Counteract Cisplatin-Induced Acute Tubular Necrosis; an Experimental Study in Rats.

Ewees M, Messiha B, Abo-Saif A, Bayoumi A, Abdel-Bakky M Front Pharmacol. 2018; 9:1155.

PMID: 30364273 PMC: 6193076. DOI: 10.3389/fphar.2018.01155.

References

Onomura M, Tsukada H, Fukuda K, Kodama M, Nakamura H, Hosokawa M . Effect of argatroban on trinitrobenzene sulfonic acid-induced colitis. J Gastroenterol Hepatol. 2000; 15(8):931-8. DOI: 10.1046/j.1440-1746.2000.02279.x. View

Danese S, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M . Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol. 2006; 102(1):174-86. DOI: 10.1111/j.1572-0241.2006.00943.x. View

Celasco G, Papa A, Jones R, Moro L, Bozzella R, Surace M . Clinical trial: oral colon-release parnaparin sodium tablets (CB-01-05 MMX) for active left-sided ulcerative colitis. Aliment Pharmacol Ther. 2009; 31(3):375-86. DOI: 10.1111/j.1365-2036.2009.04194.x. View

Xia Y, Zweier J . Measurement of myeloperoxidase in leukocyte-containing tissues. Anal Biochem. 1997; 245(1):93-6. DOI: 10.1006/abio.1996.9940. View

Yoshida H, Granger D . Inflammatory bowel disease: a paradigm for the link between coagulation and inflammation. Inflamm Bowel Dis. 2009; 15(8):1245-55. PMC: 2713811. DOI: 10.1002/ibd.20896. View

Keshavarzian A, Banan A, Farhadi A, Komanduri S, Mutlu E, Zhang Y . Increases in free radicals and cytoskeletal protein oxidation and nitration in the colon of patients with inflammatory bowel disease. Gut. 2003; 52(5):720-8. PMC: 1773652. DOI: 10.1136/gut.52.5.720. View

Borensztajn K, Bijlsma M, Groot A, Bruggemann L, Versteeg H, Reitsma P . Coagulation factor Xa drives tumor cells into apoptosis through BH3-only protein Bim up-regulation. Exp Cell Res. 2007; 313(12):2622-33. DOI: 10.1016/j.yexcr.2007.04.014. View

de Bievre M, Vrij A, Schoon E, Dijkstra G, de Jong A, Oberndorff-Klein Woolthuis A . Randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis. Inflamm Bowel Dis. 2007; 13(6):753-8. DOI: 10.1002/ibd.20085. View

Vallance B, Gunawan M, Hewlett B, Bercik P, Van Kampen C, Galeazzi F . TGF-beta1 gene transfer to the mouse colon leads to intestinal fibrosis. Am J Physiol Gastrointest Liver Physiol. 2005; 289(1):G116-28. DOI: 10.1152/ajpgi.00051.2005. View

10.

Nomura K, Liu N, Nagai K, Hasegawa T, Kobayashi I, Nogaki F . Roles of coagulation pathway and factor Xa in rat mesangioproliferative glomerulonephritis. Lab Invest. 2006; 87(2):150-60. DOI: 10.1038/labinvest.3700502. View

11.

Koo B, Chung K, Hwang K, Kim D . Factor Xa induces mitogenesis of coronary artery smooth muscle cell via activation of PAR-2. FEBS Lett. 2002; 523(1-3):85-9. DOI: 10.1016/s0014-5793(02)02948-4. View

12.

Celasco G, Moro L, Bozzella R, Mangano K, Quattrocchi C, Aiello C . Efficacy of intracolonic administration of low-molecular-weight heparin CB-01-05, compared to other low-molecular-weight heparins and unfractionated heparin, in experimentally induced colitis in rat. Dig Dis Sci. 2008; 53(12):3170-5. DOI: 10.1007/s10620-008-0299-6. View

13.

Bloom S, Kiilerich S, Lassen M, Forbes A, Leiper K, Langholz E . Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. Aliment Pharmacol Ther. 2004; 19(8):871-8. DOI: 10.1111/j.1365-2036.2004.01926.x. View

14.

Esmon C . Inflammation and thrombosis. J Thromb Haemost. 2003; 1(7):1343-8. DOI: 10.1046/j.1538-7836.2003.00261.x. View

15.

Jragh D, Khan I, Oriowo M . Colonic inflammation increases the contribution of muscarinic M2 receptors to carbachol-induced contraction of the rat colon. Med Princ Pract. 2011; 20(6):530-7. DOI: 10.1159/000328419. View

16.

Kong W, McConalogue K, Khitin L, Hollenberg M, Payan D, Bohm S . Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2. Proc Natl Acad Sci U S A. 1997; 94(16):8884-9. PMC: 23180. DOI: 10.1073/pnas.94.16.8884. View

17.

Cenac N, Coelho A, Nguyen C, Compton S, Andrade-Gordon P, MacNaughton W . Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol. 2002; 161(5):1903-15. PMC: 1850779. DOI: 10.1016/S0002-9440(10)64466-5. View

18.

Riewald M, Kravchenko V, Petrovan R, OBrien P, Brass L, Ulevitch R . Gene induction by coagulation factor Xa is mediated by activation of protease-activated receptor 1. Blood. 2001; 97(10):3109-16. DOI: 10.1182/blood.v97.10.3109. View

19.

Kubitza D, Perzborn E, Berkowitz S . The discovery of rivaroxaban: translating preclinical assessments into clinical practice. Front Pharmacol. 2013; 4:145. PMC: 3838992. DOI: 10.3389/fphar.2013.00145. View

20.

DOdorico A, Bortolan S, Cardin R, DInca R, Martines D, Ferronato A . Reduced plasma antioxidant concentrations and increased oxidative DNA damage in inflammatory bowel disease. Scand J Gastroenterol. 2002; 36(12):1289-94. DOI: 10.1080/003655201317097146. View